Kodiak Sciences Inc. (NASDAQ:KOD) spotted trading -27.79% off 52-week high price. On the other end, the stock has been noted 94.51% away from the low price over the last 52-weeks. The stock changed 0.92% to recent value of $10.99. The stock transacted 33869 shares during most recent day however it has an average volume of 173.93K shares. The company has 37.74M of outstanding shares and 27.83M shares were floated in the market.
On Sept. 04, 2019, Kodiak Sciences Inc. (NASDAQ:KOD) a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, declared that presentations on its research will be made at EURETINA 2019 Congress being held from September 5 – 8 in Paris, France.
We continue to be pleased with the promising efficacy and safety data of KSI-301, said Victor Perlroth, M.D., Kodiak’s Chief Executive Officer. At EURETINA, we will report on outcomes with over 100 patients dosed and a growing safety database with over 250 injections of KSI-301. The data being presented continue to demonstrate the potential for KSI-301 to be a first-line intravitreal anti-VEGF therapy.
Its earnings per share (EPS) expected to touch remained -42.10% for this year while earning per share for the next 5-years is expected to reach at 12.40%.
According to the most recent quarter its current ratio was 11.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of -2.52% from the mean of 20 days, -10.68% from mean of 50 days SMA and performed 20.61% from mean of 200 days price. Company’s performance for the week was 3.19%, -4.10% for month and YTD performance remained 54.79%.